Genome-scale models in human metabologenomics

A Mardinoglu, BØ Palsson - Nature Reviews Genetics, 2025 - nature.com
Metabologenomics integrates metabolomics with other omics data types to comprehensively
study the genetic and environmental factors that influence metabolism. These multi-omics …

A biological guide to glycosaminoglycans: current perspectives and pending questions

S Ricard‐Blum, RR Vivès, L Schaefer… - The FEBS …, 2024 - Wiley Online Library
Mammalian glycosaminoglycans (GAGs), except hyaluronan (HA), are sulfated
polysaccharides that are covalently attached to core proteins to form proteoglycans (PGs) …

Noninvasive detection of any-stage cancer using free glycosaminoglycans

S Bratulic, A Limeta, S Dabestani… - Proceedings of the …, 2022 - National Acad Sciences
Cancer mortality is exacerbated by late-stage diagnosis. Liquid biopsies based on genomic
biomarkers can noninvasively diagnose cancers. However, validation studies have …

High-throughput glycosaminoglycan extraction and UHPLC-MS/MS quantification in human biofluids

N Volpi, F Galeotti, F Gatto - Nature Protocols, 2024 - nature.com
Glycosaminoglycans (GAGs) are linear, unbranched heteropolysaccharides whose
structural complexity determines their function. Accurate quantification of GAGs in biofluids …

Analysis of normal levels of free glycosaminoglycans in urine and plasma in adults

S Bratulic, A Limeta, F Maccari, F Galeotti… - Journal of Biological …, 2022 - ASBMB
Plasma and urine glycosaminoglycans (GAGs) are long, linear sulfated polysaccharides that
have been proposed as potential noninvasive biomarkers for several diseases. However …

Plasma and urine free glycosaminoglycans as monitoring and predictive biomarkers in metastatic renal cell carcinoma: a prospective cohort study

F Gatto, S Bratulic, E Jonasch, A Limeta… - JCO Precision …, 2023 - ascopubs.org
PURPOSE No liquid biomarkers are approved in metastatic renal cell carcinoma (mRCC)
despite the need to predict and monitor response noninvasively to tailor treatment choices …

[HTML][HTML] Discriminating Benign from Malignant Lung Diseases Using Plasma Glycosaminoglycans and Cell-Free DNA

A Qvick, S Bratulic, J Carlsson, B Stenmark… - International Journal of …, 2024 - mdpi.com
We aimed to investigate the use of free glycosaminoglycan profiles (GAGomes) and cfDNA
in plasma to differentiate between lung cancer and benign lung disease, in a cohort of 113 …

[HTML][HTML] Plasma and urine free glycosaminoglycans as monitoring biomarkers in nonmetastatic renal cell carcinoma—a prospective cohort study

F Gatto, S Dabestani, S Bratulic, A Limeta… - European Urology Open …, 2022 - Elsevier
Background No liquid biomarkers are approved in renal cell carcinoma (RCC), making early
detection of recurrence in surgically treated nonmetastatic (M0) patients dependent on …

Plasma glycosaminoglycans and cell-free DNA to discriminate benign and malignant lung diseases

A Qvick, S Bratulic, J Carlsson, B Stenmark, C Karlsson… - medRxiv, 2024 - medrxiv.org
We aimed to investigate the use of free glycosaminoglycan profiles (GAGomes) and cfDNA
in plasma to differentiate between lung cancer and benign lung disease. GAGs were …

Interlaboratory evaluation of LC–MS-based biomarker assays

K Saito, R Goda, K Arai, K Asahina, M Kawabata… - Bioanalysis, 2024 - Taylor & Francis
Validation of biomarker assays is crucial for effective drug development and clinical
applications. Interlaboratory reproducibility is vital for reliable comparison and combination …